Inhaled non-viral delivery systems for RNA therapeutics
Acta Pharmaceutica Sinica B · 2025-05 · 15 (5) · 2402-2430
DOI: 10.1016/j.apsb.2025.03.033 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Pharmaceutica Sinica B, 2025-05. Verfasst von Cheng Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Department of Chemistry, Tsinghua University, Beijing 100084, China. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 181 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Beijing Municipal Science and Technology Commission, National Natural Science Foundation of China.
Abstract (Originalsprache)
RNA-based gene therapy has been widely used for various diseases, and extensive studies have proved that suitable delivery routes greatly help the development of RNA therapeutics. Identifying a safe and effective delivery system is key to realizing RNA therapeutics' clinical translation. Inhalation is a non-invasive pulmonary delivery modality that can enhance the retention of therapeutic agents in the lungs with negligible toxicity, thereby improving patient compliance. Inhaled RNA therapeutics are increasingly becoming an area of focus for researchers; however, only several clinical trials have explored inhaled delivery of RNA for pulmonary diseases. This review presents an overview of recent advances in inhaled delivery systems for RNA therapeutics, including viral and nonviral systems, highlighting state of the art regarding inhalation in the messenger RNA (mRNA) field. We also summarize the applications of mRNA inhalants in infectious and other lung diseases. Simultaneously, the research progresses on small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), and different types of RNA are also discussed to provide new strategies for developing RNA inhalation therapy. Finally, we clarify the challenges inhaled RNA-based therapeutics face before their widespread adoption and provide insights to help advance this exciting field to the bedside.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Department of Chemistry, Tsinghua University, Beijing 100084, China.
- State Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University,…
- Institute for Immunology, School of Basic Medical Sciences, Tsinghua University, Beijing 100084, China.
- Vascular Surgery Center, the Third Hospital of Jilin University, Changchun 130031, China.
Förderung
- National Key Research and Development Program of China
- Beijing Municipal Science and Technology Commission
- National Natural Science Foundation of China
Zitieren
APA
Huang, C., Li, H., Duan, X., Zhang, P., Qi, S., Du, J., Song, X., Tong, A., & Yu, G. (2025). Inhaled non-viral delivery systems for RNA therapeutics. Acta Pharmaceutica Sinica B, 15(5), 2402-2430. https://doi.org/10.1016/j.apsb.2025.03.033
Vancouver
Huang C, Li H, Duan X, Zhang P, Qi S, Du J, et al. Inhaled non-viral delivery systems for RNA therapeutics. Acta Pharmaceutica Sinica B. 2025;15(5):2402-2430. doi:10.1016/j.apsb.2025.03.033
BibTeX
@article{Huang2025,
author = {Huang, Cheng and Li, Hongjian and Duan, Xing and Zhang, Peidong and Qi, Shaolong and Du, Jianshi and Song, Xiangrong and Tong, Aiping and Yu, Guocan},
title = {Inhaled non-viral delivery systems for RNA therapeutics},
journal = {Acta Pharmaceutica Sinica B},
year = {2025},
volume = {15},
number = {5},
pages = {2402--2430},
doi = {10.1016/j.apsb.2025.03.033}
}
EUVIMED